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Abstract
These studies focused on a new radiolabeling technique with copper ( Cu) and zirconium ( Zr) for positron emission64 89
tomography (PET) imaging using a CD45 antibody. Synthesis of 64Cu-CD45 and 89Zr-CD45 immunoconjugates was
performed and the evaluation of the potential toxicity of radiolabeling human peripheral blood stem cells (hPBSC) was
assessed in vitro (viability, population doubling times, colony forming units). hPBSC viability was maintained as the dose of
64Cu-TETA-CD45 increased from 0 (92%) to 160 mCi/mL (76%, p.0.05). Radiolabeling efficiency was not significantly
increased with concentrations of 64Cu-TETA-CD45 .20 mCi/mL (p.0.50). Toxicity affecting both growth and colony
formation was observed with hPBSC radiolabeled with $40 mCi/mL (p,0.05). For 89Zr, there were no significant differences
in viability (p.0.05), and a trend towards increased radiolabeling efficiency was noted as the dose of 89Zr-Df-CD45
increased, with a greater level of radiolabeling with 160 mCi/mL compared to 0–40 mCi/mL (p,0.05). A greater than 2,000
fold-increase in the level of 89Zr-Df-CD45 labeling efficiency was observed when compared to 64Cu-TETA-CD45. Similar to
64Cu-TETA-CD45, toxicity was noted when hPBSC were radiolabeled with $40 mCi/mL (p,0.05) (growth, colony formation).
Taken together, 20 mCi/mL resulted in the highest level of radiolabeling efficiency without altering cell function. Young
rhesus monkeys that had been transplanted prenatally with 256106 hPBSC expressing firefly luciferase were assessed with
bioluminescence imaging (BLI), then 0.3 mCi of 89Zr-Df-CD45, which showed the best radiolabeling efficiency, was injected
intravenously for PET imaging. Results suggest that 89Zr-Df-CD45 was able to identify engrafted hPBSC in the same locations
identified by BLI, although the background was high.
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Introduction
In vivo imaging techniques with sufficient sensitivity to detect
small quantities of cells are needed to determine the safety and
efficiency of new stem/progenitor cell therapies for a spectrum of
human diseases. A crucial gap for effective in vivo imaging
technologies in stem cell research is the need to improve detection
sensitivity, and to ensure that images can accurately identify
transplanted cells at a given anatomical location. Nuclear
medicine techniques, particularly positron emission tomography
(PET), have much higher sensitivity than magnetic resonance
imaging (MRI), and unlike bioluminescence imaging (BLI), which
has similar sensitivity, can provide three-dimensional quantitative
images. Outcomes with PET can also be translated from animal
models to humans since many of the radiotracers are currently
used in a human clinical setting [1–4].
We previously reported techniques for radiolabeling
stem and progenitor cells with 64Cu- pyruvaldehyde-bis
(N4-methylthiosemicarbazone) (PTSM) for PET imaging [5].
Studies showed that a minimum of 2.56104 CD34+ hematopoietic
cells (1.1 pCi/cell) and 6.256103 mesenchymal stromal cells
(4.4 pCi/cell) could be detected, and that each cell type had a
different level of sensitivity to the radiolabeling technique. 64Cu
has a half-life of 12.7 hours allowing cells to be tracked for
approximately 2–3 days, and we demonstrated a radiolabeling
dose that avoided cell toxicity. We also adapted this method to
radiolabel and track transplanted renal precursors differentiated
from human embryonic stem cells in fetal rhesus monkeys in vivo
[6]. These studies showed effective radiolabeling techniques for
renal precursors without toxicity, and correlative imaging
outcomes with PET, BLI, and at the tissue level.
The overall goal of the current studies was to explore a new
radiolabeling method for PET imaging specifically related to
human peripheral blood stem cells (hPBSC) as a prototype cell
population. We also utilized an established rhesus monkey model
of prenatal hematopoietic stem cell transplantation [7] for
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preliminary in vivo studies. Direct radiolabeling of cells provides
the best contrast-to-noise environment for cell detection because
there is essentially no background when the majority of detected
signal comes from the cells. Since all of the reagents and
techniques proposed are specific for human cells, the methodol-
ogies can be directly translated to humans. In these studies we
investigated both 64Cu and 89Zr using a radioimmunoconjugate
technique that targets the cell surface instead of an internalized
agent such as PTSM, which we have previously used. 89Zr has a
half-life of 3.3 days providing an opportunity to monitor cells for
longer time periods when compared to 64Cu, and also provides a
more favorable decay profile (22.7% positron emission, 77.3%
electron capture). Since tracking of radiolabeled cells is limited by
half-life we also considered a new way to begin to assess
engraftment by targeting a cell-surface marker in vivo, specifically
CD45 (common leukocyte antigen). Our primary objectives were
to first effectively synthesize the radioimmunoconjugates using
CD45, to test the safety and efficiency of radiolabeling hPBSC and
identify an effective radiolabeling paradigm, then to assess the
ability to identify transplanted hPBSC in the monkey model. We
utilized PET imaging in vivo in these studies in two ways: post-
injection of radioimmunoconjugated hPBSC to track the injected
cells, and after direct injection of the radioimmunoconjugate with
the goal of homing to engrafted hPBSC. The results of these
studies have shown new methods for synthesizing 64Cu-CD45 and
89Zr-CD45 immunoconjugates and optimum radiolabeling meth-
ods for PET imaging.
Materials and Methods
Animals and Ethics Statement
All animal protocols were approved prior to implementation by
the Institutional Animal Care and Use Committee (IACUC) at the
University of California, Davis, and all procedures conformed to
the requirements of the Animal Welfare Act. Activities related to
animal care including housing, feeding, and environmental
enrichment were performed in accordance with IACUC-approved
standard operating procedures (SOPs) at the California National
Primate Research Center (http://www.cnprc.ucdavis.edu). No
animals were euthanized for the imaging studies described.
Normally cycling, adult female rhesus monkeys (Macaca mulatta)
(N= 6) with a history of prior pregnancy were bred and identified
as pregnant, using established methods [8]. Activities related to
animal care (diet, housing) were performed according to Primate
Center IACUC-approved SOPs. Fetuses were transplanted
prenatally with human male donor hPBSC (256106 cells/fetus)
using an intraperitoneal approach as previously described,
monitored sonographically during gestation, and newborns
delivered by cesarean-section at term then raised in the nursery
according to established protocols for postnatal studies [7,8]. PET
imaging studies were conducted when animals were approximately
3 months postnatal age.
hPBSC
CD34+ hPBSC were obtained from a commercial source
(AllCells, Berkeley, CA) and cryopreserved using a controlled rate
cryopreservation protocol in aliquots as previously reported [7].
All hPBSC used in these studies were from the same male donor.
Transduction
Aliquots of cells used for transplantation were thawed and
plated in non-tissue culture-treated 25 cm2 flasks coated with
4 mg/cm2 of the RetroNectin (Takara Bio Inc., Kyoto, Japan).
hPBSC were incubated overnight in X-Vivo 15 serum-free
medium (Lonza, Hopkinton, MA) supplemented with 2 mM L-
glutamine, 100 units/mL penicillin, and 100 mg/mL streptomy-
cin, and containing 100 ng/mL of thrombopoietin (TPO), Flt3-
Ligand (Flt3-L), and stem cell factor (SCF) (R&D Systems,
Minneapolis, MN). Cells were resuspended in fresh medium
containing cytokines and transduced with an HIV-1-derived
lentiviral vector expressing firefly luciferase under the control of
the MND promoter at a final vector concentration of 86107 TU/
mL, with protamine sulfate at 4 mg/mL (American Pharmaceu-
tical Partners, Inc., Schaumburg, IL) using established methods
[6]. After 2 h, the medium volume was doubled and cells were
incubated at 37uC with 5% CO2 for 6–8 h. A second aliquot of
the lentiviral vector was added to the cells and incubated
overnight. Cells were washed with fresh medium and incubated
overnight, then washed and cultured in fresh medium for 2 days.
Prior to transplantation, cells were washed in sterile phosphate
buffered saline (PBS) three times, and cell counts and viability were
determined using trypan blue exclusion.
Radiochemistry
A mouse anti-human CD45 antibody (BD Biosciences, San
Jose, CA) was used for these studies. Bromacetoamido benzyl
TETA (BAT) was kindly provided by Claude F. Meares,
University of California, Davis. 64Cu was obtained from Wash-
ington University and 89Zr from IBA (Belgium). Copper (II)
chloride (Fisher Scientific, Pittsburgh, PA) and zirconium (IV)
chloride (Sigman-Aldrich, St. Louis, MO) were used for carrier
added experiments. Sephadex G50 (Sigma) was used for molecular
sieving filtration and 0.22 mm SLGV syringe end filters (Millipore,
Billerica, MA) were used for final filtration of radiolabeled
antibody. All solvents and buffer reagents were reagent grade or
better, purchased from commercial sources, and used without
additional purification. Aqueous buffers were prepared with
18 mV purified water (Millipore). Isocratic molecular sieving
HPLC (Waters, Milford, MA) was performed with a 30067.8 mm
5 m Biosep SEC-2000 column (Phenomenex, Torrance, CA),
eluted in 0.1 M sodium phosphate (aq), pH 6.8, at 1.5 mL per
minute, with UV (280 nm) and radioanalytic (Bioscan, Inc.,
Washington, DC) detection. In this system, radiolabeled antibody
eluted at 6.4 min, and 64Cu- and 89Zr-EDTA eluted at 9.8 min.
Mouse anti-human CD45 antibody was conjugated to the
copper-chelating agent TETA by combining antibody, 2-imi-
nothiolane (2IT) (Sigma), and BAT at concentrations of 0.07 mM,
1.0 mM, and 2.0 mM, respectively, in 0.1 M ammonium phos-
phate, pH 9 (0.25 mL) for 1 h at 37uC. TETA-CD45 was purified
and transferred to 0.1 M ammonium acetate, pH 5, by molecular
sieving filtration. Three TETA molecules were conjugated per
antibody, as determined by copper-binding assay with carrier-
added 64Cu and antibody assay by UV absorbance (280 nm).
Five radiolabelings of 64Cu-TETA-CD45 were performed. 64Cu
in dilute HCl (5.8 to 7.5 mCi) was buffered with ammonium
acetate, then added to CD45-TETA (0.2 to 0.8 mg) in 0.1 M
ammonium acetate, pH 5 (0.12 to 0.27 mL). The radiolabeling
solutions were incubated for 30 to 60 min at 37uC. Certified
0.1 M disodium ethylene diamine tetraacetic acid (EDTA) (Fisher
Scientific) was added to a final concentration of 10 mM, to
scavenge unchelated 64Cu. 64Cu-CD45-TETA was purified and
transferred to PBS by molecular sieving filtration, and filtered.
Radiochemical yield and product purity were determined by
analytical HPLC of EDTA-challenged radiolabeling solution and
purified 64Cu-TETA-CD45, respectively. The mean radiochem-
ical yield was 75%, and all doses exceeded 95% radiochemical
purity, with a mean activity of 17 mCi per mg of antibody.
Radiolabeling for Stem Cell PET Imaging
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Mouse anti-human CD45 antibody was conjugated to the
zirconium-chelating agent desferrioxamine by combining antibody
and desferrioxamine-p-SCN (Df-p-SCN) (Macrocyclics Inc.,
Dallas, TX) at concentrations of 32–45 mM and 200–430 mM,
respectively, in 0.1 M sodium carbonate, pH 9 (0.35 to 0.51 mL)
[9]. The molar ratios of Df-p-SCN to antibody were 6 to 12. The
conjugation solutions were incubated for 1–2 h at 40uC. Df-CD45
was purified and transferred to 0.1 M HEPES, pH 7, by
molecular sieving filtration. One to two Df molecules were
conjugated per antibody, as determined by zirconium-binding
assay with carrier-added 89Zr and antibody assay by UV
absorbance (280 nm).
Five radiolabelings of 89Zr-Df-CD45 were performed. 89Zr in
1 M oxalic acid (2.2 to 4.4 mCi) was buffered with 2 M sodium
carbonate, then added to Df-CD45 (0.40 to 0.66 mg) in 0.2 M
HEPES, pH 7 (0.39 to 0.69 mL), The radiolabeling solutions were
incubated for 1–2 h at room temperature. EDTA was added to a
final concentration of 5 mM, to scavenge unchelated 89Zr. 89Zr-
Df-CD45 was purified and transferred to saline by molecular
sieving filtration, and filtered. Radiochemical yield and product
purity were determined by analytical HPLC of EDTA-challenged
radiolabeling solution and purified 89Zr-Df-CD45, respectively.
The mean radiochemical yield was 89%, and all doses exceeded
95% radiochemical purity, with a mean activity of 4.2 mCi per mg
of antibody.
hPBSC Radiolabeling
Cell binding, internalization, and potential toxicity of 64Cu and
89Zr immunoconjugates were assessed in triplicate as described
below. Briefly, ,66106 hPBSC/mL were incubated with the
immunoconjugate for 1 h (37uC) and cells washed three times with
PBS, then radioactivity in the wash buffer and cell pellet counted.
To assure that 64Cu or 89Zr was not released over time, the
radiolabeled hPBSC were incubated in rhesus monkey serum
under physiologic conditions, and the fraction of radioactivity
associated with the cells measured at time points out to 3 (64Cu)
and 7 (89Zr) days. The following assessments were performed in
triplicate: (1) incubation time (hourly for 1–4 h); (2) amount of
radioactivity for the incubation (mCi/cells/mL); (3) viability of the
cells after incubation and over 48 h (trypan blue); and (4) efflux of
radioactivity. Post-radiolabeling hPBSC were assessed in triplicate
in hematopoietic colony forming unit (CFU) assays in parallel with
unlabeled cells using established protocols [5].
hPBSC were incubated at room temperature for 30 min with
64Cu-TETA-CD45 or 89Zr-Df-CD45 at concentrations of 0, 20,
40, 80, or 160 mCi/mL in triplicate. A gamma count was taken on
radiolabeled cells and medium obtained from the final wash with
cell viability assessed using trypan blue. After radiolabeling, cells
were incubated for 1 week at 37uC and 5% CO2. Cell counts were
obtained for each dose with proliferation assessed by determining
population doubling times using established protocols [5].
Radiolabeled cells were also plated in Methocult and incubated
for 10 days for CFU assay. Differentiation potential of radiola-
beled cells was assessed by counting erythroid (burst forming unit-
erythroid, BFU-E) and myeloid (CFU-granulocyte macrophage,
CFU-GM) colonies [5,7]. A theoretical upper limit of radiolabel-
ing efficiency was determined using QuantiBRITETM PE beads
following the manufacturer’s protocol.
In vivo Imaging
BLI was performed according to established protocols [10,11]
once animals were sedated with telazol and after an intravenous
injection of 100 mg/kg D-Luciferin using a Xenogen IVISH200
Imaging System with Living Image Software analysis (Caliper Life
Sciences, Alameda, CA). Each animal was imaged using four views
(anterior-posterior, posterior-anterior, right and left lateral) at each
imaging session in a light tight chamber, and whole body images
obtained with quantification performed. Bioluminescence and
photographic images were superimposed using Living Image 2.50
software. Regions of interest (ROIs) were defined by selecting
areas showing bioluminescence. Numbers of total photons/sec/
cm2 detected in ROIs were recorded.
The microPET P4 imaging system (Siemens Preclinical
Solutions, Inc., Malvern, PA) has a 22 cm bore, 20 cm transaxial
field of view, and 8 cm axial field of view, and sensitivity of the
scanner is 2.25% at the center of the field of view with an energy
window of 250–750 keV and a timing window of 10 ns (default
values) [12]. With maximum a posteriori (MAP) reconstruction
incorporating an accurate system model (standard reconstruction
algorithm used), image resolution is ,1.8 mm isotropically (6 mL
volumetric resolution). PET signals were analyzed and quantified
with AMIDE (amide.sourceforge.net) software.
Animals were sedated with telazol and supplemented with
ketamine as needed and injected intravenously with radiolabeled
hPBSC (N=2) or ,0.3 mCi of 64Cu-TETA-CD45 or 89Zr-Df-
CD45 (N= 4; 2 per radioimmunoconjugate). Each animal was
placed on the scanner bed (supine) and the upper abdominal area
was positioned in the center field of view based on images obtained
by BLI. Static PET scans were acquired for ,60 min on day 0,
day 2, day 5, and day 9 post-injection. All listmode data were
sorted into 3D sinograms using a span of 3 and a ring difference of
31. Images were reconstructed with a 2D OSEM reconstruction
algorithm with an imaging matrix of 12861286112 with a
corresponding voxel size of 0.1960.1961.21 mm3.
Statistical Analysis
Results are reported as the mean 6 standard error of the mean
and calculated using Microsoft Excel (Microsoft, Redmond, WA).
Statistical significance (p,0.05) was determined by analysis of
variance or two-sided Student’s t-test analysis.
Results
64Cu-CD45 and 89Zr-CD45 Immunoconjugates
To investigate the feasibility of tracking cells after transplanta-
tion with PET, optimal conditions were explored using a human-
specific CD45 antibody and radiolabeling hPBSC with either
64Cu-TETA-CD45 or 89Zr-Df-CD45. In a preliminary study the
selected CD45 clone HI30 showed a very high specificity for
human cells with no binding to rhesus monkey cells. The CD45
antibody was successfully conjugated to 64Cu or 89Zr after several
in vitro studies.
hPBSCs radiolabeled with each of the immunoconjugates were
incubated with secondary antibodies against CD45 for analysis by
flow cytometry. Results showed no significant differences in the
percentage and mean fluorescence of hPBSC labeled with the
immunoconjugates when compared to control cells (data not
shown). Thus, no internalization was observed.
Optimum Labeling Dose
Cryopreserved hPBSC were thawed and plated in 12-well
culture plates at 16106 cells per well in X-VIVO 15TM medium
supplemented with SCF, TPO, and FLT3L (50 ng/mL each) as
noted above. Cells were incubated at room temperature for
30 min with 64Cu-TETA-CD45 or 89Zr-Df-CD45 with the range
of concentrations identified.
For 64Cu, no significant decrease in viability was observed as
the dose of 64Cu-TETA-CD45 increased from 0 (92%) to
Radiolabeling for Stem Cell PET Imaging
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160 mCi/mL (76%; p.0.05) (Figure 1). Radiolabeling efficiency
was not significantly increased with concentrations of 64Cu-
TETA-CD45 greater than 20 mCi/mL (p.0.5). For 0, 20, 40, 80,
and 160 m/mL, activities were 0.003, 0.023, 0.022, 0.031, and
0.028 pCi/cell, respectively. Toxicity affecting both growth and
colony formation (BFU-E, CFU-GM) was observed with cells
radiolabeled with $40 m/mL (p,0.05). Population doublings
observed for 0, 20, 40, 80, and 160 mCi/mL were 2.360.1,
2.260.2, 1.760.1, 1.360.1, and 0.960.4, respectively. CFU-GM
identified at each of the doses were 17.162.1, 30.266.1, 8.465.3,
7.864.2, and 8.063.1, respectively. No toxicity was observed in
BFU-E colony formation. Peak theoretic radiolabeling efficiency
was calculated to be 10-fold more (0.32 pCi/cell) than the greatest
measured radioactivity per cell, suggesting further optimization
may be able to be achieved.
For 89Zr, there were no significant differences in viability
observed between the dose groups evaluated (p.0.05) (Figure 2).
As shown in Figure 2, a trend in increasing radiolabeling efficiency
was observed as the dose of 89Zr-Df-CD45 increased with a
significantly greater level of radiolabeling for 160 mCi/mL
compared to 0–40 m/mL (p,0.05). A greater than 2,000 fold-
increase in the level of 89Zr-Df-CD45 labeling efficiency was
observed when compared to 64Cu-TETA-CD45. Similar to the
study using 64Cu-TETA-CD45, toxicity was observed with cells
radiolabeled with$40 mCi/mL (p,0.05) when growth and colony
formation (BFU-E, CFU-GM) were evaluated. Taken together,
20 mCi/mL showed the highest level of efficiency without altering
cell function.
Biodistribution of Immunoconjugates
Based on outcome, in vivo studies with 64Cu-TETA-CD45 were
not pursued because the per-cell activity was significantly lower
when compared to 89Zr-Df-CD45. When these results were
compared to our prior studies with 64Cu-PTSM, a greater level of
cell labeling was noted which may be related to PTSM which
labels the cells by passive diffusion [5] in contrast to radio-
immunoconjugates that target the cell surface. The half-life of
64Cu is also relatively short (12.7 days) thus allowing 3 days of
imaging whereas 89Zr has a half-life of 3.3 days allowing cells to be
tracked for approximately 2 weeks. Two animals injected with
56106 cells radiolabeled with 64Cu-PTSM at 20 mCi/mL showed
signals in the lung (white arrow) and liver (red arrow) immediately
post-injection (Figure 3). Radioactivity was also detected in the
lumbar spine (yellow arrow). Animals showed no detectable level
of radioactivity in subsequent scanning sessions. For short-term
cell trafficking studies, 56106 hPBSC radiolabeled with 89Zr-Df-
CD45 at the optimal dose of 20 mCi/mL were injected
intravenously (N= 2), and animals were imaged 24 and 48 h
post-injection, then 1 week after transplantation. No detectable
PET signals were observed immediately following injection (data
not shown). These studies suggest that 64Cu-PTSM may be more
efficient for direct radiolabeling hPBSC and in vivo detection.
Efficiency of 89Zr-CD45 Immunoconjugate to Identify
Engrafted Human Cells
The CD45 antibody was directly bound to 89Zr and used as a
method to identify engrafted cells that had previously been
Figure 1. 64Cu-TETA-CD45 radiolabeling of hPBSC. hPBSC were radiolabeled with 0, 20, 40, 80, or 160 mCi/mL of 64Cu-TETA-CD45. No
significant changes in cell viability or degree of labeling were observed with increasing concentrations. A decline in cell growth and colony formation
was observed when cells were incubated with 64Cu-TETA-CD45 at a concentration .20 mCi/mL.
doi:10.1371/journal.pone.0077148.g001
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confirmed by BLI (prenatal hPBSC transplant, postnatal imaging).
Animals transplanted prenatally with 256106 hPBSC expressing
firefly luciferase were injected with 0.3 mCi of 89Zr-Df-CD45
intravenously at 3 months postnatal age and PET imaging
performed at 0, 1, 3, 5, and 9 days post-injection (N= 2). Monkey
#1 showed a high level of bioluminescence (3.06107 p/s) in the
right abdomen whereas very low signals (2.16106 p/s) were
observed for Monkey #2 (Figure 4). As anticipated, high
background PET signals were observed in the liver prior to day
5 (data not shown). PET imaging on day 5 post-injection showed
CD45 labeling (yellow arrow) within the peritoneum of Monkey
#1, which was consistent with the corresponding BLI image.
Monkey #2 showed signals in the liver with no detectable
radioactivity observed on day 9 post-injection.
Discussion and Conclusions
These studies focused on new methods for the development of
CD45 immunoconjugates with 64Cu and 89Zr. Nontoxic hPBSC
radiolabeling conditions were identified and an optimal dose
selected for in vivo imaging studies. The outcome of these
preliminary investigations suggest that the 64Cu immunoconjugate
was not as efficient when compared to radiolabeling cells with
64Cu-PTSM, and that the signal from intravenously injected
radiolabeled hPBSC (using either immunoconjugate) was below
the level of detection by the microPET scanner used in these
studies. Outcomes also suggest that the direct injection of 89Zr-Df-
CD45 was the most efficient in identifying engrafted hPBSC in the
rhesus monkey host. While these studies were conducted in a small
group of animals, they report for the first time new stem/
progenitor cell radiolabeling methods in vitro and the potential
applications in vivo.
We have previously reported the optimization of radiolabeling
rhesus monkey stem and progenitor cells with 64Cu-PTSM
without evidence of radiotoxicity [5]. PTSM is a lipophilic
redox-active carrier molecule that can deliver 64Cu into the cell
passively. When Cu(II)-PTSM is reduced to Cu(I)-PTSM, Cu(I) is
Figure 2. 89Zr-Df-CD45 radiolabeling of hPBSC. hPBSC were labeled with 0, 20, 40, 80, or 160 mCi/mL of 89Zr-Df-CD45. No significant changes in
cell viability were observed with increasing concentrations. However, a greater degree of radiolabeling was observed with 80 and 160 mCi/mL of 89Zr-
Df-CD45. A decline in cell growth and colony formation was noted when cells were incubated with 89Zr-Df-CD45 at a concentration .20 m/mL.
doi:10.1371/journal.pone.0077148.g002
Figure 3. Short-term tracking of hPBSC radiolabeled with 89Cu-
PTSM by PET. hPBSC were radiolabeled with 20 mCi/mL of 64Cu-PTSM.
Cells radiolabeled with 64Cu-PTSM were detected in the lung (white
arrow) and liver (red arrow) on the day of postnatal transplant (day 0).
Cells were observed in the liver (red arrow) and spinal column (yellow
arrow) 24 h post-injection (day 1).
doi:10.1371/journal.pone.0077148.g003
Radiolabeling for Stem Cell PET Imaging
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captured by intracellular macromolecules while the neutral PTSM
diffuses out of the cell. This method has been shown to result in
efficient intracellular radiolabeling of target cells [5]. However,
radiotoxic Auger electrons have a penetration of 0.02–10 mm with
very high DNA toxicity within this range. 64Cu emits a 6.84-keV
Auger electron with a penetration range of approximately 5 mm
and can potentially result in DNA damage, thus, requiring a lower
dose for labeling to prevent radiotoxicity. Thus, in this study, a
human-specific antibody to a membrane protein, a pan-hemato-
poietic marker CD45, was used for radiolabeling rather than the
intracellular approach with PTSM. We hypothesized that labeling
of the cell membrane using the human-specific CD45 antibody
conjugated to 64Cu or 89Zr would increase radiolabeling efficiency
while minimizing radiotoxicity. However, no increase in radiola-
beling efficiency was observed in these studies. In addition, the
antibody-based membrane labeling approach showed a similar
level of radiotoxicity compared to the intracellular PTSM
radiolabeling method. These findings suggest that the concentra-
tion of radioisotope in the labeling solution is an important factor
in determining radiotoxicity when compared to the quantity and
location of 64Cu bound to cellular components. Similar findings
were observed when cells were radiolabeled using the CD45
antibody conjugated to 89Zr.
In our in vitro radiolabeling studies, CD45 antibodies conjugated
to 89Zr consistently resulted in a higher labeling efficiency
compared to 64Cu at the same concentration of radiotracers.
When hPBSC radiolabeled with the CD45 antibody and 89Zr
were directly injected in vivo and subsequently imaged with PET,
no detectable signals were observed above background. For
comparison, hPBSC radiolabeled with 64Cu-PTSM showed clear
signals in the lung and spinal column, with high background in the
liver. These findings suggest that there are insufficient CD45
molecules on the plasma membrane, which were estimated to be
1.386105 antibody binding sites per cell (unpublished findings), to
provide sufficient antibody binding for radiolabeling and PET
imaging. However, this finding does not preclude the possibility of
identifying another membrane-bound molecule that is present at a
higher frequency than CD45 for radiolabeling purposes. In
addition, a polyclonal antibody with a greater number of binding
sites per target molecule could potentially be explored, and a
combination of these factors may enhance radiolabeling efficiency.
Current instrumentation and methodology for PET is optimized
for detecting and quantifying relatively high levels of radiotracer
concentrations that are distributed throughout the body. The most
common example is 18F-fluorodeoxyglucose (FDG) for imaging
glucose metabolism. The imaging environment for cell studies in
vivo is vastly different. The total amount of radioactivity inside the
subject is typically 3 orders of magnitude lower (mCi versus mCi),
and the distribution of this activity is sparse and confined to cell
location. Therefore, issues related to background become critical
in identifying very weak signals, and the image reconstruction
methodologies typically employed have not been optimized for this
task. A major limitation of commercially available PET scanners is
the use of detector materials that incorporate lutetium that has a
naturally occurring isotope, Lu-176, which makes the detectors
slightly radioactive. We have focused on this potential limitation
by comparing PET scanners based on the scintillator lutetium
oxyorthosilicate (LSO) and bismuth germanate (BGO) [13]. These
related investigations have determined that radioactive LSO-based
PET scanners do not perform as well when compared to those
with non-radioactive materials such as BGO for imaging low
activity sources. Optimizing parameters such as energy windows
on the LSO-based scanners was also found to only lead to
marginal improvements.
In conclusion, these studies report methods for developing
CD45 immunoconjugates with 64Cu and 89Zr. Preliminary
imaging studies also indicate that the 64Cu immunoconjugate
was not as efficient for in vivo imaging when compared to
radiolabeling cells with 64Cu-PTSM and the signal from injected
radiolabeled hPBSC (using either immunoconjugate) was below
the level of detection by the microPET scanner used in these
studies. Of the approaches tested, direct injection of 89Zr-Df-
CD45 was found to be the most efficient in identifying engrafted
hPBSC. Additional studies with immunoconjugates and related
cell labeling techniques are important in order to develop sensitive
and safe methods to monitor cell trafficking and cell fate for future
human application.
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Figure 4. BLI and PET imaging of transplanted hPBSC. hPBSC
expressing firefly luciferase were transplanted prenatally in the late first
trimester [7]. At ,3 months postnatal age D-luciferin was injected
intravenously and BLI was performed to confirm the anatomical
location of transplanted cells, then 89Zr-Df-CD45 was injected. Monkey
#1 showed a high level of bioluminescence in the abdominal region.
Both animals showed strong PET signals on day 5 post-injection of 89Zr-
Df-CD45 within the liver. The muscular component of the peritoneum
(white and yellow arrows) of Monkey #1 showed corresponding BLI
and PET signals.
doi:10.1371/journal.pone.0077148.g004
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